Concise review: Combining human leukocyte antigen g and mesenchymal stem cells for immunosuppressant biotherapy

Stem Cells

Volumn 31, Issue 11, 2013, Pages 2296-2303

  Naji, Abderrahim ^a,f   Rouas Freiss, Nathalie ^a,b   Durrbach, Antoine ^c,d   Carosella, Edgardo D ^a,d   Sensébé, Luc ^e   Deschaseaux, Frédéric ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c INSERM U1014   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

^f KOCHI UNIVERSITY   (Japan)

Author keywords

HLA G; Immunosuppression; Mesenchymal stem cells; Transplantation tolerance

Indexed keywords

ALLOANTIGEN; BETA INTERFERON; CYCLOSPORIN; HLA G ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; PHYTOHEMAGGLUTININ; PROSTAGLANDIN E2; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL (TOPIC); HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

IMMUNOSUPPRESSION, HLA-G; MESENCHYMAL STEM CELLS; TRANSPLANTATION TOLERANCE;

ANIMALS; BIOLOGICAL THERAPY; HLA-G ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84887920448     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1494     Document Type: Article

References (87)

1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74. (Pubitemid 27161245)
2. Deschaseaux F, Charbord P. Human marrow stromal precursors are alpha 1 integrin subunitpositive. J Cell Physiol 2000; 184: 319-325. (Pubitemid 30625494)
3. Quirici N, Soligo D, Bossolasco P et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002; 30: 783-791. (Pubitemid 34835685)
4. Frenette PS, Pinho S, Lucas D et al. Mesenchymal stem cell: Keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 31: 285-316.
5. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317. (Pubitemid 44269669)
6. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
7. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009; 17: 939-946.
8. Lee RH, Seo MJ, Pulin AA et al. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009; 113: 816-826.
9. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001. (Pubitemid 36857986)
10. Lee RH, Pulin AA, Seo MJ et al. Intravenous hMSCs improve myo-cardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
11. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009; 4: 206-216.
12. Mathieu M, Bartunek J, El Oumeiri B et al. Cell therapy with autolo-gous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction. J Thorac Cardiovasc Surg 2009; 138: 646-653.
13. Bianco P, Cao X, Frenette PS et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 19: 35-42.
14. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchy-mal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301. (Pubitemid 44464698)
15. Wood KJ, Goto R. Mechanisms of rejection: Current perspectives. Transplantation 2012; 93: 1-10.
16. Metalidis C, Kuypers DR. Emerging immunosuppressive drugs in kidney transplantation. Curr Clin Pharmacol 2011; 6: 130-136.
17. Metalidis C, Kuypers D. Immunosuppressive therapy after kidney transplantation: Current and new strategies. Minerva Urol Nefrol 2011; 63: 1-19.
18. Le Blanc K., Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
19. Kuzmina LA, Petinati NA, Parovichnikova EN et al. Multipotent mes-enchymal stromal cells for the prophylaxis of acute graft-versus-host disease - A phase II study. Stem Cells Int 2012; 2012: 968213.
20. Herrmann R, Sturm M, Shaw K et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: A phase 1 study. Int J Hematol 2012; 95: 182-188.
21. Hoogduijn MJ, Popp FC, Grohnert A et al. Advancement of mesen-chymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010; 90: 124-126.
22. Ricart E. Current status of mesenchymal stem cell therapy and bone marrow transplantation in IBD. Dig Dis 2012; 30: 387-391.
23. Zanone MM, Favaro E, Miceli I et al. Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab 2010; 95: 3788-3797.
24. Phinney DG. Biochemical heterogeneity of mesenchymal stem cell populations: Clues to their therapeutic efficacy. Cell Cycle 2007; 6: 2884-2889.
25. Isakova IA, Baker K, Du Treil M et al. Age- and dose-related effects on MSC engraftment levels and anatomical distribution in the central nervous systems of nonhuman primates: Identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 2007; 25: 3261-3270. (Pubitemid 350294452)
26. Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008; 10: 320-330. (Pubitemid 351983156)
27. De Miguel M.P., Fuentes-Julian S, Blazquez-Martinez A et al. Immuno-suppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 2012; 12: 574-591.
28. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490. (Pubitemid 40691430)
29. Di Nicola M., Carlo-Stella C, Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
30. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25 highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
31. Plumas J, Chaperot L, Richard M.J., et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604. (Pubitemid 43090404)
32. Gieseke F, Schutt B, Viebahn S., et al. Human multipotent mesenchy-mal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 2007; 110: 2197-2220.
33. Ortiz LA Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007; 104: 11002-11007. (Pubitemid 47175216)
34. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032. (Pubitemid 47258180)
35. Nasef A, Mazurier C, Bouchet S., et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 2008; 253: 16-22.
36. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
37. Liotta F, Angeli R, Cosmi L., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26: 279-289.
38. Prevosto C, Zancolli M, Canevali P., et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92: 881-888. (Pubitemid 350144234)
39. Hammer A. Immunological regulation of trophoblast invasion. J Reprod Immunol 2011; 90: 21-28.
40. Fanchin R, Gallot V, Rouas-Freiss N et al. Implication of HLA-G in human embryo implantation. Hum Immunol 2007; 68: 259-263. (Pubitemid 46497521)
41. Steinborn A, Varkonyi T, Scharf A et al. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. Am J Reprod Immunol 2007; 57: 277-286. (Pubitemid 46394840)
42. Selmani Z, Naji A, Gaiffe E et al. HLA-G is a crucial immunosup-pressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87:S62-S66.
43. Nasef A, Mathieu N, Chapel A et al. Immunosuppressive effects of mesenchy-mal stem cells: Involvement of HLA-G. Transplantation 2007; 84: 231-237. (Pubitemid 47205757)
44. Caumartin J, Favier B, Daouya M et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007; 26: 1423-1433. (Pubitemid 46398697)
45. Rouas-Freiss N., Khalil-Daher I, Marchal-Bras Goncalves R et al. Role of HLA-G in maternal-fetal immune tolerance. Transplant Proc 1999; 31: 724-725. (Pubitemid 29127646)
46. Kovats S, Main EK, Librach C et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220-223. (Pubitemid 120031455)
47. Carosella ED, Favier B, Rouas-Freiss N et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111: 4862-4870.
48. Rouas-Freiss N., Khalil-Daher I, Riteau B et al. The immunotolerance role of HLA-G. Semin Cancer Biol 1999; 9: 3-12. (Pubitemid 29178538)
49. Naji A, Menier C, Maki G et al. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 26: 1889-1892.
50. Fournel S, Aguerre-Girr M, Huc X et al. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164: 6100-6104. (Pubitemid 30408785)
51. Gregori S, Tomasoni D, Pacciani V et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116: 935-944.
52. Deschaseaux F, Gaillard J, Langonne A et al. Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J 2013; 27: 2977-2987.
53. Moreau P, Carosella E, Gluckman E et al. [Alternative transcripts of the MHC of the non-classical class I HLA-G gene in the in trophoblast during the first pregnancy trimester and in the placenta at term]. C R Acad Sci iii 1995; 318: 837-842.
54. Naji A, Durrbach A, Carosella ED et al. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 2007; 68: 233-239. (Pubitemid 46497518)
55. Kapasi K, Albert SE, Yie S et al. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000; 101: 191-200.
56. Kanai T, Fujii T, Kozuma S et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 2001; 7: 195-200. (Pubitemid 32148347)
57. Huang YH, Zozulya AL, Weidenfeller C et al. T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol 2009; 86: 273-281.
58. Moreau P, Flajollet S, Carosella ED. Non-classical transcriptional regulation of HLA-G: An update. J Cell Mol Med 2009; 13: 2973-2989.
59. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells 2010; 28: 585-596.
60. Rond S, Gonzalez A, Gonzalez AS et al. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways. Immunology 2005; 116: 297-307. (Pubitemid 41532122)
61. Menard C, Pacelli L, Bassi G et al. Clinical-grade mesenchymal stro-mal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: Standardization of immune quality controls. Stem Cells Dev 2013; 22: 1789-1801.
62. Rizzo R, Lanzoni G, Stignani M et al. A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosup-pressive potential. Cytotherapy 2011; 13: 523-527.
63. Yang HM, Sung JH, Choi YS et al. Enhancement of the immunosup-pressive effect of human adipose tissue-derived mesenchymal stromal cells through HLA-G1 expression. Cytotherapy 2012; 14: 70-79.
64. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
65. Taupin P. OTI-010 Osiris therapeutics/JCR pharmaceuticals. Curr Opin Investig Drugs 2006; 7: 473-481. (Pubitemid 43772988)
66. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12: 383-396.
67. Tan J, Wu W, Xu X et al. Induction therapy with autologous mesen-chymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 307: 1169-1177.
68. Sato K, Ozaki K, Mori M et al. Mesenchymal stromal cells for graft-versus-host disease: Basic aspects and clinical outcomes. J Clin Exp Hematop 2010; 50: 79-89.
69. Naji A, Le Rond S, Durrbach A et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: Novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007; 110: 3936-3948. (Pubitemid 350248449)
70. Lila N, Carpentier A, Amrein C et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000; 355: 2138. (Pubitemid 30364668)
71. Luque J, Torres MI, Aumente MD et al. Soluble HLA-G in heart transplantation: Their relationship to rejection episodes and immuno-suppressive therapy. Hum Immunol 2006; 67: 257-263. (Pubitemid 44255786)
72. Lila N, Amrein C, Guillemain R et al. Soluble human leukocyte antigen-G: A new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant 2007; 26: 421-422. (Pubitemid 46509735)
73. Qiu J, Terasaki PI, Miller J et al. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6: 2152-2156. (Pubitemid 44199549)
74. Liang S, Zhang W, Horuzsko A. Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006; 36: 2457-2471. (Pubitemid 44420602)
75. Otsuru S, Gordon PL, Shimono K et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 120: 1933-1941.
76. Jones E, Yang X. Mesenchymal stem cells and bone regeneration: Current status. Injury 42: 562-568.
77. Kon E, Filardo G, Roffi A et al. Bone regeneration with mesenchymal stem cells. Clin Cases Miner Bone Metab 9: 24-27.
78. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313. (Pubitemid 29124367)
79. Totey S, Pal R. Adult stem cells: A clinical update. J Stem Cells 2009; 4: 105-121.
80. Barry FP, Murphy JM. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36: 568-584. (Pubitemid 38324589)
81. Knowlton D. Fifth Annual Stem Cell Summit. Idrugs 2010; 13: 235-238.
82. Ren G, Chen X, Dong F et al. Concise review: Mesenchymal stem cells and translational medicine: Emerging issues. Stem Cells Transl Med 2012; 1: 51-58.
83. Lin Y, Hogan WJ. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hema-tol 2011; 2011: 427863.
84. Lian Q, Lye E, Suan Yeo K et al. Derivation of clinically compliant MSCs from CD105+, CD24-differentiated human ESCs Stem Cells 2007; 25: 425-436. (Pubitemid 46232798)
85. Hwang NS, Varghese S, Lee HJ et al. In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci USA 2008; 105: 20641-20646.
86. Giuliani M, Oudrhiri N, Noman ZM et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 2011; 118: 3254-3262.
87. Yen BL, Chang CJ, Liu KJ et al. Brief report - Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosup-pressive effects toward natural killer cells as well as T lymphocytes. Stem Cells 2009; 27: 451-456.